Facebook Twitter Instagram
    • Personalities/Staff
    • Jobs
    • Calendar
    • Keeping it Local
    • Contest Rules
    • Contact Us
    • Login
    RSS Facebook Twitter
    News Radio KMAN
    ESB's Managing Your Money
    • Local/State News
      • Manhattan
      • Riley County
      • Wamego
      • Pottawatomie County
      • Fort Riley
      • Geary County
      • State News
      • RCPD Reports
    • Weather
    • Sports
      • High School Sports
        • Scores
      • Scoreboard Saturday
      • K-State Sports
      • Student-Athlete of the Week
    • On Demand
      • In Focus
      • Who’s On In Focus
      • The Game
      • Managing Your Money by ESB Financial
      • Wildcat Insider
    • Obituaries
    • Message Us
      • Birthday/Anniversary
    Listen
    News Radio KMAN
    You are at:Home»Local News»K-State Activity»K-State licenses technology for coronavirus and norovirus compounds with goal of antiviral treatment

    K-State licenses technology for coronavirus and norovirus compounds with goal of antiviral treatment

    0
    By KMAN Staff on February 28, 2020 K-State Activity, Local News
    Kansas State University College of Veterinary Medicine virologists Yunjeong Kim, front, and Kyeong-Ok "KC" Chang, back, along with medicinal chemist William Groutas at Wichita State University, have developed technology that K-State Innovation Partners has licensed to Cocrystal Pharma Inc. for possible antiviral drugs to treat coronaviruses and noroviruses.
    Kansas State University College of Veterinary Medicine virologists Yunjeong Kim, front, and Kyeong-Ok “KC” Chang, back, along with medicinal chemist William Groutas at Wichita State University, have developed technology that K-State Innovation Partners has licensed to Cocrystal Pharma Inc. for possible antiviral drugs to treat coronaviruses and noroviruses.

    Kansas State University has licensed a technology that may lead to production of an antiviral drug to treat coronaviruses and noroviruses.

    This comes as worldwide concern increases over the novel cornavirus outbreak, COVID-19. A release from the university Friday said two K-State College of Veterinary Medicine virologists, Yungeong Kim and Kyeong-Ok “KC” Chang along with Wichita State University medicinal chemist William Groutas have been using grants from the National Institutes of Health to work on human norovirus therapeutics. They recently received a $3.7 million grant to develop antiviral drugs to treat Middle East Respiratory Syndrome, better known as the MERS human coronavirus. Their work extends to other viruses with simila viral protease including, but not limited to the newly emerged COVID-19 that’s been dominating world headlines.

    Currently no antiviral drugs are available for human norovirus or coronaviruses, which includes COVID-19, MERS and the SARS virus.

    The university said that may change as a result of a new license agreement between K-State and Cocrystal Pharma Inc., a clinical stage biotechnology company that is discovering and developing novel antiviral therapeutics in an effort to treat coronavirus and norovirus infections. Cocrystal intends to pursue research and development of these antiviral compounds, including preclinical and clinical development.

    The research team of Chang and Kim have reportedly collaborated for years on the development of antiviral compounds to combat devastating viral diseases in humans and animals.

    The licensing agreement was coordinated by K-State Innovation Partners, formerly known as the Kansas State University Research Foundation. Read more at k-state.edu.

     

    Share this:

    • Facebook
    • Twitter
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    KMAN Staff
    • Website
    • Facebook
    • Twitter

    Related Posts

    USD 384 to interview superintendent candidates this week

    Sports officials testify in support of bill that would give them legal protection from unruly spectators

    One person jailed after fistfight lands victim in hospital

    Comments are closed.

    Listen Live Here
    Listen Live - Mobile

    Categories

    EEO Report

    FCC Public File

    FCC Applications


    Follow @1350kman on Twitter · Manhattan Broadcasting Company is an equal opportunity employer.
    Manhattan Broadcasting does not discriminate in sale of advertising on the basis of race, gender, or ethnicity, and will not accept advertising which does so discriminate. © 2022 Manhattan Broadcasting Company.

    Type above and press Enter to search. Press Esc to cancel.